SCHEMBL6432948

SCHEMBL6432948

COC(=O)C1(S(=O)(=O)N2CCC(c3ccc(-c4cccc(OCCOCc5ccccc5)n4)c(C)c3)CC2)CCN(Cc2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.51
MMP3 P08254 7/20 0.51
MMP1 P03956 4/20 0.51
MMP9 P14780 4/20 0.51
MMP14 P50281 2/20 0.51
GLP1R P43220 3/20 0.37
DRD2 P14416 2/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MMP13 P45452 2/20 0.35
ADAM17 P78536 2/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
FFAR1 O14842 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6968646 0.94 MMP2 (0.51) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6971129 0.86 MMP2 (0.48) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6971907 0.83 MMP2 (0.65) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6433723 0.81 MMP2 (0.64) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6433286 0.81 MMP2 (0.64) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6433952 0.80 MMP2 (0.57) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6435679 0.79 CYP3A4 (0.46) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6436456 0.79 MMP2 (0.63) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6433803 0.77 MMP2 (0.52) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6433657 0.77 MMP2 (0.52) MMP2MMP3MMP1MMP9MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP claimed
US-6511993-B1 Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes PFIZER INC. 2003-01-28 US claimed
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP disclosed
US-6511993-B1 Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes PFIZER INC. 2003-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP1 1/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.